Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments

Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments

KANSAS CITY, Kan., May 31, 2018 /PRNewswire/ — Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the appointment of Jeff Conroy and Jeff Hargroves to its Board